All medicines have risks. Risk management is used to ensure that the potential benefits of a medicine exceed its potential risks, and to minimize those risks. The traditional tools used to manage the risks of prescription medicines have been the prescription status itself, labeling for healthcare professionals, and the requirement that manufacturers monitor and report to regulatory authorities adverse events that occur with use of the medicine. In the past decades, additional steps have been taken to manage more actively the risks of certain marketed medicinal products. These measures have included increased communication to patients and healthcare professionals, and measures to restrict the usage, in various ways, of certain medicines. Risk management systems are ideally scientifically driven, functional throughout a product's life cycle, proactive in nature, and inclusive of all stakeholders. The principal current challenges center on advancing the science of risk management in terms of developing systems-based approaches to minimizing the risk of medicines and developing strategies and evidence of the effectiveness of risk minimization strategies. In addition, in the EU, developing a more focused approach to risk management is an ongoing challenge, with the aim of rationalizing resources to where they can have the most impact.

Manzo, C., Cochino, E., Merchant, L., Mazzaglia, G. (2019). Risk Management. In B. Strom, S. Kimmel, S. Hennessy (a cura di), Pharmacoepidemiology 6th Edition (pp. 581-616). John Wiley & Sons [10.1002/9781119413431.ch24].

Risk Management

Mazzaglia G
2019

Abstract

All medicines have risks. Risk management is used to ensure that the potential benefits of a medicine exceed its potential risks, and to minimize those risks. The traditional tools used to manage the risks of prescription medicines have been the prescription status itself, labeling for healthcare professionals, and the requirement that manufacturers monitor and report to regulatory authorities adverse events that occur with use of the medicine. In the past decades, additional steps have been taken to manage more actively the risks of certain marketed medicinal products. These measures have included increased communication to patients and healthcare professionals, and measures to restrict the usage, in various ways, of certain medicines. Risk management systems are ideally scientifically driven, functional throughout a product's life cycle, proactive in nature, and inclusive of all stakeholders. The principal current challenges center on advancing the science of risk management in terms of developing systems-based approaches to minimizing the risk of medicines and developing strategies and evidence of the effectiveness of risk minimization strategies. In addition, in the EU, developing a more focused approach to risk management is an ongoing challenge, with the aim of rationalizing resources to where they can have the most impact.
Capitolo o saggio
Drug regulation; EU risk management plan; Risk assessment; Risk communication; Risk evaluation and mitigation strategy (REMS); Risk management; Risk minimization; Risk mitigation;
Risk management, regulatory, risk minimization, Impact evaluation
English
Pharmacoepidemiology 6th Edition
Strom, B; Kimmel, S; Hennessy, S
2019
9781119413417
John Wiley & Sons
581
616
Manzo, C., Cochino, E., Merchant, L., Mazzaglia, G. (2019). Risk Management. In B. Strom, S. Kimmel, S. Hennessy (a cura di), Pharmacoepidemiology 6th Edition (pp. 581-616). John Wiley & Sons [10.1002/9781119413431.ch24].
reserved
File in questo prodotto:
File Dimensione Formato  
2019 PHARMACOEPI - RISK MANAGEMENT.pdf

Solo gestori archivio

Tipologia di allegato: Submitted Version (Pre-print)
Dimensione 839.23 kB
Formato Adobe PDF
839.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260325
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
Social impact